anti-EGFRvIII mRNA vaccine (Providence Therapeutics)

N/A

Report date: 2026/01/26 17:59:05

Base Information

Drug Nameanti-EGFRvIII mRNA vaccine (Providence Therapeutics)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProvidence Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesProvidence Therapeutics Holdings Inc
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A